Learning Lab brought to you by Centre for Human Drug Research (CHDR): How CHDR Adds Value to Early Phase Clinical Drug Studies: Development and Validation of Methodology to Prove Pharmacology in Healthy Subjects and Demonstrate Target Engagement in Patients

Enjoy complimentary lunch! Due to space constraints, seats will be available on a first-come, first-served basis and may run out before the event starts; therefore, please plan to arrive early.

This lunch symposium illustrates how CHDR-the Netherlands adds value to early phase clinical drug development. The symposium discusses the challenges and strategies involved in establishing proof of pharmacology in humans, in vivo and ex vivo, demonstrating target engagement, and proof-of-concept in patients. The presentation then explores the complexities of translating preclinical success to meaningful clinical impact, highlighting the significance of Phase I clinical trials and the multifaceted nature of proof of concept. The presentation will include examples of clinicals studies in different therapeutic areas illustrating the use of mechanistic pharmacodynamic measurements early on in clinical development.

Brought to you by:



This event is sponsored by an ASCPT Partner organization. The content of the session is provided for informational purposes only and does not constitute or imply ASCPT's endorsement, recommendation, or approval of a specific institution, service, employer, or content.